Xeris Biopharma Holdings, Inc. XERS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product revenue, net by Product | |||||
| Gvoke | $94.11M+13.6% | $82.83M+23.5% | $67.05M+27.6% | $52.53M+35.0% | |
| Keveyis | $47.65M-3.8% | $49.53M-12.8% | $56.77M+15.1% | $49.31M+376% | |
| Recorlev | $139.28M+117% | $64.28M+118% | $29.55M+298% | $7.43M— | |
| Royalty, contract and other revenue | $8.84M+37.4% | $6.43M-39.0% | $10.55M+971% | $985K+218% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Xeris Biopharma Holdings, Inc. break its business down?
- Xeris Biopharma Holdings, Inc. (XERS) reports product revenue, net by product across 4 parts — Gvoke, Keveyis, Recorlev and Royalty, contract and other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Xeris Biopharma Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Xeris Biopharma Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
